Loading...
Market
Will a peer-reviewed study show significant survival benefit from AI-based ROBO1 CAR T cell therapy for glioblastoma by mid-2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Publication in a reputable peer-reviewed medical journal
Story
Researchers Develop AI-Based Immunotherapy for Glioblastoma Using ROBO1 CAR T Cells
Aug 2, 2024, 09:09 AM
Researchers are pioneering a new immunotherapy approach using artificial intelligence (AI) to treat glioblastoma, a highly aggressive form of brain cancer. This innovative method, developed by scientists at institutions including Keck School of Medicine at USC and Cambridge University, aims to transform cancer treatment. The approach involves developing AI models to create new tools for combating cancer. A promising therapy treatment has been discovered that can kill glioblastoma cells by targeting a newly-discovered brain pathway, as reported in Nature Medicine. Additionally, the use of ROBO1 CAR T cells has shown potential as a potent immunotherapy for glioblastoma and other invasive brain cancers. This Canadian-developed treatment could significantly impact the fight against the most aggressive brain cancers.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Increased survival rate • 25%
Reduced secondary cancer rate • 25%
Improved quality of life • 25%
Other • 25%
New drug approval • 25%
Major clinical trial success • 25%
New treatment guidelines • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Positive results • 25%
Negative results • 25%
Inconclusive results • 25%
Trial halted • 25%